A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

* Male or female (of non-child bearing potential) between 18 and 70 years of age with Body Mass Index ≥18 to \<38 kg/m2. * Chronic HCV genotype 3 infection prior to study enrollment and has never received antiviral treatment for HCV. * Subject has plasma HCV RNA level \> 10,000 IU/mL at Screening. * Sexually active males must be sterile, have male partners only, or agree to use two effective forms of birth control for 7 months after stopping study drug.

* History of severe, life-threatening or other significant sensitivity to any drug. * Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab). * Prior therapy for the treatment of HCV. * Any current or past clinical evidence of cirrhosis. * Any cause of liver disease other than chronic HCV-infection. * HCV genotype co-infection with any other HCV genotype. * Use of contraindicated medications within 2 weeks or 10 half-lives of dosing.